Table 1.
Characteristics of AML samples analyzed by RNAseq.
| Characteristics | No. of AML |
|---|---|
| Number of patients | 100 |
| Age (median, years) | 53 (22–77) |
| Gender | |
| Male | 55 |
| Female | 45 |
| WHO diagnosis | |
| AML with t(9;11); KMT2A-MLLT3a | 4 |
| AML with inv(16); CBFB-MYH11a | 10 |
| AML with t(8;21); RUNX1-RUNX1T1a | 3 |
| Acute promyelocytic leukemia with t(15;17); PML-RARAa | 2 |
| AML with inv(3); GATA2, MECOMa | 2 |
| AML with t(6;9); DEK-NUP214 | 1 |
| AML with mutated NPM1b | 35 |
| Acute monoblastic/monocytic leukemia | 11 |
| AML with myelodysplasia-related changes | 13 |
| AML NOS with maturati | 9 |
| AML NOS with minimal differentiation | 1 |
| AML NOS without maturation | 12 |
| Acute myelomonocytic leukemia | 3 |
| Therapy-related AML | 2 |
| AML | |
| Primary | 95 |
| Relapse | 5 |
| Source | |
| Bone marrow (BM) | 78 |
| Peripheral blood (PB) | 22 |
| Blast percentage (median) | 75 (13–99) |
| Karyotypec | |
| Normal karyotype | 45 |
| Complex karyotype | 8 |
| Abnormal karyotype | 37 |
| No metaphases | 2 |
| FLT3-ITDb | 34 |
aRecurrent fusion transcripts CBFB-MYH11 inv(16)(p13q22), KMT2A-MLLT3 t(9;11)(p21;q23), RUNX1-RUNX1T1 t(8;21)(q22;q22), and PML-RARA t(15;17)(q24;q21) as well as chromosomal translocation GATA2, MECOM inv(3)(q21q26) were detected by fluorescence in situ hybridization (FISH) on 200 interphases per probe set.
bGenotyping for NPM1 and FLT3-ITD mutations was performed by routine diagnostic PCR on genomic DNA followed by electrophoretic fragment size analysis.
cKaryotype was determined by cytogenetics on at least 20 metaphases per case.